The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Comparison of Adefovir and Tenofovir in the Treatment of Lamivudine–Resistant Hepatitis B Virus Infection
Abstract
Adefovir dipivoxil was recently approved for the treatment of wild–type and lamivudine–resistant hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate, a congender of adefovir that is used in the treatment of HIV infected patients, has recently been shown to also be effective in patients with lamivudine–resistant HBV infection. We therefore compared the two substances in a study of 53 patients defined by high HBV DNA (>6 log10 copies/mL) levels and genotypic evidence of lamivudine resistance. Thirty–five patients received tenofovir for 72 to 130 weeks, and 18 received adefovir for 60 to 80 weeks. Changes in HBV DNA levels were followed for the complete period of 48 weeks. Early viral kinetics were compared on matched subgroups of 5 patients each. Individually, all tenofovir–treated patients showed a strong and early suppression of HBV DNA within a few weeks whether they were coinfected with HIV or were without comorbidity. In contrast, considerable individual variations in HBV DNA decline were observed in the adefovir group. Thus at week 48, only 44% of these patients had HBV DNA levels below 105 copies/mL in contrast to 100% of the tenofovir–treated patients ( P = .001). No severe side effects were noticed in either group. No evidence of phenotypic viral resistance could be demonstrated in the tenofovir–treated patients in the long term (up to 130 weeks). In conclusion , tenofovir may become an effective alternative for the treatment of patients with lamivudine–resistant HBV infection. (Hepatology 2004;40:1421-1425.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 564
Peters, M. G., Hann, H. W., Martin, P., Heathcote, E. J., Buggisch, P., Rubin, R., Bourliere, M., Kowdley, K., Trepo, C., Gray, D. F., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.051 · Cited by 552
Long-term therapy of chronic hepatitis B with lamivudine
Lau, D. T.-Y., Khokhar, F. M., Doo, E., Ghany, M. G., Herion, D., Park, Y., Kleiner, D. E., Schmid, P., Condreay, L. D., Gauthier, J., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.17912 · Cited by 348
Dore, G. J., Cooper, D. A., Pozniak, A. L., DeJesus, E., Zhong, L., Miller, M. D., Lu, B., Cheng, A. K., & Teams, T. 9. A. 9. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/380398 · Cited by 253
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B
Kuo, A., Dienstag, J. L., & Chung, R. T. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00017-5 · Cited by 123
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802878 · Cited by 1,181
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Liaw, Y.-F., Leung, N., Kao, J.-H., Piratvisuth, T., Gane, E., Han, K.-H., Guan, R., Lau, G. K. K., Locarnini, S., & for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver (2008) · Hepatology International · doi:10.1007/s12072-008-9080-3 · Cited by 867
Acyclic nucleoside phosphonates: a key class of antiviral drugs
Clercq, E. D., & Holý, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1877 · Cited by 688
Management of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., & Tobias, H. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.021 · Cited by 558
Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A., Ghany, M. G., Pawlotsky, J.-M., Liaw, Y.-F., Mizokami, M., & Kuiken, C. (2007) · Hepatology · doi:10.1002/hep.21698 · Cited by 447
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., Tobias, H., & Wright, T. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00312-4 · Cited by 359
Medical Virology of Hepatitis B: how it began and where we are now
Gerlich, W. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-239 · Cited by 349
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
De Clercq, E., & Field, H. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706446 · Cited by 336
van Bömmel, F., de Man, R. A., Wedemeyer, H., Deterding, K., Petersen, J., Buggisch, P., Erhardt, A., Hüppe, D., Stein, K., Trojan, J., et al. (2010) · Hepatology · doi:10.1002/hep.23246 · Cited by 330
Self-citationRapti, I., Dimou, E., Mitsoula, P., & Hadziyannis, S. J. (2007) · Hepatology · doi:10.1002/hep.21534 · Cited by 323
Viral Hepatitis in HIV Infection
Koziel, M. J., & Peters, M. G. (2007) · New England Journal of Medicine · doi:10.1056/nejmra065142 · Cited by 322
Viral hepatitis and HIV coinfection
Sulkowski, M. S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.009 · Cited by 316
van Bömmel, F., Zöllner, B., Sarrazin, C., Spengler, U., Hüppe, D., Möller, B., Feucht, H.-H., Wiedenmann, B., & Berg, T. (2006) · Hepatology · doi:10.1002/hep.21253 · Cited by 287
Self-citationSide effects of long-term oral antiviral therapy for hepatitis B
Fontana, R. J. (2009) · Hepatology · doi:10.1002/hep.22885 · Cited by 272
Flink, H. J., van Zonneveld, M., Hansen, B. E., de Man, R. A., Schalm, S. W., Janssen, H. L. A., & for the HBV 99-01 Study Group* (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00418.x · Cited by 262
Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus
Delaney, W. E., Ray, A. S., Yang, H., Qi, X., Xiong, S., Zhu, Y., & Miller, M. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00138-06 · Cited by 259
Antiviral Drug Resistance: Mechanisms and Clinical Implications
Strasfeld, L., & Chou, S. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.001 · Cited by 254
Mortality from cirrhosis: lack of progress over the last 35 years
Gluud, C. (2005) · Gut · doi:10.1136/gut.2005.072876 · Cited by 17
Metadata
- Authors
- van Bömmel, F., Wünsche, T., Mauss, S., Reinke, P., Bergk, A., Schürmann, D., Wiedenmann, B., & Berg, T.
- Venue
- Hepatology
- Published
- 2004-12
- Volume
- 40
- Issue
- 6
- Pages
- 1421-1425
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2058388169
- Cited by
- 389
- References
- 8
- FWCI
- 34.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.